<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-11-20</loc>
      <lastmod>2026-11-22T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-22T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Five Under 5: Top Oncology Videos for the Week of 11/20]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-11-15</loc>
      <lastmod>2026-11-21T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-21T13:00:00Z</news:publication_date>
        <news:title><![CDATA[The OncFive: Top Oncology Articles for the Week of 11/15]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/dr-gutierrez-on-considerations-for-investigating-sar445877-in-mss-crc</loc>
      <lastmod>2026-11-20T21:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T21:30:00Z</news:publication_date>
        <news:title><![CDATA[Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/daraxonrasib-plus-gemcitabine-nab-paclitaxel-generates-durable-responses-in-first-line-metastatic-pdac</loc>
      <lastmod>2026-11-20T21:25:46.715Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T21:25:46.715Z</news:publication_date>
        <news:title><![CDATA[Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/trofuse-015-meets-primary-os-end-point-with-sac-tmt-in-third-line-or-later-gastroesophageal-adenocarcinoma</loc>
      <lastmod>2026-11-20T20:42:43.169Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T20:42:43.169Z</news:publication_date>
        <news:title><![CDATA[TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma]]></news:title>
      </news:news>
	</url></urlset>